Pneumovirus Infections is an indication for drug development with over 180 pipeline drugs currently active. According to GlobalData, preregistered drugs for Pneumovirus Infections have a 75% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Pneumovirus Infections compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pneumovirus Infections overview

Pneumoviridae is a family of negative-strand RNA viruses in the order Mononegavirales. Humans, cattle, and rodents serve as natural hosts. Respiratory tract infections are associated with member viruses such as human respiratory syncytial virus. Pneumoviruses are pleomorphic, capable of producing spherical and filamentous, enveloped virions. Pneumoviruses are intermediate in size between viruses of the families Paramyxoviridae and Orthomyxoviridae. Cytoplasmic inclusions are considerably more dense than those of other viruses in the family. Human metapneumovirus infection is very similar to the common cold; it is an upper respiratory infection.

For a complete picture of PTSR and LoA scores for drugs in Pneumovirus Infections, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.